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Abstract
Background: Lymphovascular invasion (LVI) and lymph node metastasis are conventional pathological factors 
associated with an unfavorable prognosis of urothelial carcinoma of the upper urinary tract (UC-UUT), but little is 
known about the molecular mechanisms underlying LVI and nodal metastasis in this disease. Rac1 small GTPase (Rac1) 
is essential for tumor metastasis. Activated GTP-bound Rac1 (Rac1 activity) plays a key role in activating downstream 
effectors known as Pak (21-activated kinase), which are key regulators of cytoskeletal remolding, cell motility, and cell 
proliferation, and thus have a role in both carcinogenesis and tumor invasion.
Methods: We analyzed Rac1 activity and Pak1 protein expression in matched sets of tumor tissue, non-tumor tissue, 
and metastatic lymph node tissue obtained from the surgical specimens of 108 Japanese patients with UC-UUT.
Results: Rac1 activity and Pak1 protein levels were higher in tumor tissue and metastatic lymph node tissue than in 
non-tumor tissue (both P < 0.0001). A high level of Rac1 activity and Pak1 protein expression in the primary tumor was 
related to poor differentiation (P < 0.05), muscle invasion (P < 0.01), LVI (P < 0.0001), and lymph node metastasis (P < 
0.0001). Kaplan-Meier survival analysis showed that an increase of Rac1 activity and Pak1 protein was associated with a 
shorter disease-free survival time (P < 0.01) and shorter overall survival (P < 0.001). Cox proportional hazards analysis 
revealed that high Rac1 activity, Pak1 protein expression and LVI were independent prognostic factors for shorter 
overall and disease-free survival times (P < 0.01) on univariate analysis, although only Pak1 and LVI had an influence (P < 
0.05) according to multivariate analysis.
Conclusions: These findings suggest that Rac1 activity and Pak1 are involved in LVI and lymph node metastasis of UC-
UUT, and may be prognostic markers for this disease.
Background
Urothelial carcinoma of the upper urinary tract (UC-
UUT) is relatively uncommon, accounting for <10% of all
urothelial malignancies, but its incidence is increasing
[1]. Many patients who undergo curative resection
develop systemic metastases within a few years, so the
prognosis of this cancer is poor [2], presumably due to
occult micrometastasis at the time of surgery because of
the thin walls and rich lymphatic drainage of the ureter.
Metastasis involves the spread of tumor cells from the
primary tumor to a distant site [3], and is the major cause
of human cancer death. Various pathological studies have
shown that poorly differentiated cancer, muscle invasion,
lymph node metastasis, and lymphovascular invasion
(LVI) are associated with recurrence and are unfavorable
prognostic factors for UC-UUT [2,4,5]. Thus, LVI and
lymph node metastasis are used to predict the prognosis.
Despite their clinical importance, little is known about
the molecular mechanisms of LVI and lymph node
metastasis, making it important to examine the factors * Correspondence: kamait@dokkyomed.ac.jp
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playing a role in LVI and lymph node metastasis of UC-
UUT.
Members of the Rho small GTPases family, prototype
RhoA, Rac1, and Cdc42, are involved in the regulation of
a variety of cellular processes, such as organization of the
microfilament network, cell-cell contact, and malignant
transformation, and also perform essential and special-
ized functions during organization of the actin cytoskele-
ton [6]. RhoA regulates the formation of stress fibers and
focal adhesions in cells, while Rac1 regulates the forma-
tion of lamellipodia and membrane ruffling, and Cdc42
regulates the formation of filopodia [6,7]. In addition, a
number of investigations have established a significant
role of GTPases from the Rho family in several human
tumors, including UC-UUT [7,8]. Rac1 is ubiquitously
expressed and exists in two conformational states. In
response to extracellular signals, interconversion of these
two states occurs via guanine nucleotide exchange factors
(GEFs), which convert the inactive GDP-bound form of
Rac1 to its active GTP-bound form, while GTPase-acti-
vating proteins (GAPs) inactivate proteins (GAPs) inacti-
vate Rac1. After activation, Rac1 interacts with various
specific effectors to coordinate the activation of a multi-
tude of signaling cascades that influence diverse physio-
logical outcomes. The Pak (p21-activated kinase) serine/
threonine kinases have recently been found to be key reg-
ulators of cytoskeletal remolding, cell motility, and cell
proliferation, with a role in both carcinogenesis and cellu-
lar invasion [9]. It has been reported that Pak1, the best
characterized member of this family, shows increased
expression and activity in human cancers [9-11]. Multiple
signalling pathways converge to promote activation of
Pak1 through both small GTPases and several of the
tyrosine kinases. In turn, activated Pak1 regulates diverse
cellular functions. Pak1 binds to Rac1 in a GTP-depen-
dent manner, after which activated Pak1 regulates cellular
functions such as cytoskeletal dynamics, cell adhesion,
and transcription [9]. Rac1 signals through Pak1 to acti-
vate c-Jun N-terminal kinase (JNK) [9], placing Rac1
between the Ras small GTPases (Ras) and mitogen-acti-
vated protein kinase (MAPK) in the signaling cascade
from growth factor receptors and v-Src to activation of
JNK [12,13]. Gao et al. reported that a low molecular
weight inhibitor of Rac GTPase targeting the activation of
Rac by GEF was able to reverse the tumor cell phenotype
associated with deregulation of Rac [14]. In addition, sev-
eral low molecular weight inhibitors have been shown to
interfere with Pak kinase activity or function [9]. These
findings suggest that Rac1 and Pak may be potential
molecular targets for the treatment of cancer.
Regarding the expression of Rho family GTPases in
human cancers, most previous reports were based on the
investigation of protein expression levels by Western
blotting and immunohistochemistry. However, only the
active GTP-binding form (active GTPase) recognizes tar-
get proteins and generates a response. Increased activity
of Rac1 and overexpression of Pak1 are associated with
the progression of cancer, but most of the evidence has
come from cell culture studies. Therefore, the role of
active Rac1 GTPase and its downstream effector needs to
be studied by using surgically resected samples of human
tumors to better assess their contribution to human can-
cer. Accordingly, we examined the expression of active
GTP-bound Rac1 (Rac1 activity) and its downstream
effector Pak1 in the primary tumors and metastatic
lymph nodes of patients with UC-UUT by Western blot-
ting, and also assessed the relation of these molecules
with clinicopathological features. There have been few
reports about the simultaneous analysis of Rac1 and Pak1
in human tumor tissues. Such information could be use-
ful for developing individualized treatment strategies and
could potentially improve the design and application of
adjuvant therapy for UC-UUT.
Methods
Patients and tissues
Between 1995 and 2006, surgical specimens of UC-UUT
were obtained from 108 consecutive Japanese patients
(77 men and 31 women) aged 42 to 89 years (mean age:
71.9 years) with newly diagnosed primary transitional cell
carcinoma (TCC) of the renal pelvis and ureter without
distant metastasis (cTanyNanyM0). These specimens were
reviewed in the present study. All patients routinely
underwent imaging investigations (CT and/or MRI)
before surgery to acquire information for staging. The
follow-up time ranged from 5 to 132 months, with a
median follow-up period of 41 months. Patients under-
went surgery before receiving any other therapy.
During nephroureterectomy, the patients also under-
went lymphadenectomy when enlarged lymph nodes
were confirmed. In all patients, tumor tissue, non-tumor
tissue, and lymph node tissue were acquired from the
resected specimens after removing excess stromal tissue.
Then the tissues were embedded in OCT tissue com-
pound (Miles, Elkhart, IN, USA) and stored at - 80°C
according to the method described previously [15]. The
grade and stage of each tumor were classified according
to the TNM system [16]. This study was conducted in
accordance with the Helsinki Declaration and institu-
tional review board approval in Dokkyo Medical Univer-
sity Hospital was obtained. In addition, each patient
signed a consent form approved by the Committee on
Human Rights in Research of our institution.
Systemic chemotherapy with methotrexate, vinblastine,
Adriamycin, and cisplatin (M-VAC) was given to the 16
patients who had lymph node metastasis at nephroure-
terectomy, as well as those in whom lymph node metasta-Kamai et al. BMC Cancer 2010, 10:164
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sis (14 patients) or distant metastasis (5 patients) was
detected postoperatively [17].
Rac1 activation assay and Western blotting
Tumor tissue and normal tissue specimens were carefully
dissected free of stromal tissue. To measure Rac1 activa-
tion, we performed a Rho-binding domain (RBD) affinity
precipitation assay for Rac1-GTP using a specific Rac1
antibody according to the manufacturer's protocol
(Cytoskeleton, BK126, Denver, CO) [18-20]. Tissue
extracts were obtained from 50 mg of each type of tissue
and the protein concentration was determined by Brad-
ford's method (BIO-RAD, Hercules, CA). Then the
extracts were equalized with ice cold cell lysis buffer con-
taining 25 mM Tris (pH 7.5), 10 mM MgCl2, 0.5 M NaCl,
and 1% Triton X-100 to obtain identical protein concen-
trations. Next, equivalent amounts of protein were added
to 15 μl of Pak (p21-activated kinase)-RBD beads and
incubated at 4°C on a rotor for 1 hr. Then the Pak-RBD
beads solution was centrifuged at 3,000 g for 1 min at 4°C
and supernatant was removed. After washing the pellet
three times, the bound proteins were analyzed by West-
ern blotting, as described previously [21]. Briefly, 25 μg of
GTP-Rac1 bound to Pak-RBD beads was separated by
SDS-PAGE (5-20% gradient gel) and electrotransferred to
a polyvinylidene difluoride membrane (Sequi-Blot PVDF
membranes; BIO-RAD). Rac1 His-tagged protein (100,
50, and 10 ng/μl) was also run on the gel as a standard. If
the intensity of the immunoreactive band was outside the
range of 10-100 ng/μl, samples were diluted with loading
buffer and run on the gel again. Total cell lysate with GDP
was employed as a negative control. After membranes
were blocked to eliminate nonspecific binding, mem-
brane-bound proteins were probed with an anti-Rac1
monoclonal antibody (Cytoskeleton, BK126). Then the
membranes were washed and incubated with a horserad-
ish peroxidase-conjugated secondary antibody. Anti-
body-bound protein bands were visualized by
chemiluminescence, the blotted membrane was sub-
jected to densitometry by scanning with a ChemiDoc
XRS-J imaging scanner (BIO-RAD), and the data were
analyzed with NIH Image software. The mean value for
three experiments was obtained with each tissue speci-
men.
For measurement of Pak1, 50 μg of cytosolic protein
was separated by SDS-PAGE (12.5% gel) and elec-
trotransferred to a polyvinylidene difluoride membrane
(Immobilon-P membrane; Millipore, Bedford, MA). After
the membrane was blocked, the bound proteins were
probed with specific antibodies (Santa Cruz Biotechnol-
ogy; sc-881, Santa Cruz, CA) and a primary antibody for
beta actin (Santa Cruz Biotechnology, Santa Cruz, CA).
Hela cells were used as a positive control for Rac1 and
Pak1 expression. Next, the membranes were washed and
then incubated with horseradish peroxidase-conjugated
secondary antibodies. Antibody-bound protein bands
were visualized by chemiluminescence, the blotted mem-
brane was scanned for densitometry with a PDI imaging
scanner (Agfa Japan, Tokyo), and the data were analyzed
with NIH Image software. Expression of active Rac1 and
Pak1 was determined relative to that of beta actin in the
tumor tissue and corresponding normal tissue speci-
mens, after which relative expression was calculated. For
quantification of these proteins, the relative amount of
Rac1 or Pak1 in tumor tissue was expressed as a ratio of
the optical density of the band obtained from the tumor
specimen to that from the corresponding normal tissue
(which was set at 1.0) by densitometric analysis as
described previously [21-23]. The mean values for tumor
tissue and non-tumor tissue were calculated from three
experiments [21,22].
Immunohistochemistry
To support the data obtained by Western blotting, immu-
nohistochemistry was performed with the same antibod-
ies utilized for Western blotting on 3 tumors from
patients with lymph node metastases (pN+) and 5 tumors
from patients without nodal metastasis (pN-), as
described previously [20-22].
Statistical analysis
Western blotting data were analyzed by the Mann-Whit-
ney  U  test to compare two groups [21,22], or by the
Kruskal-Wallis test for comparisons among three or more
groups. Spearman's rank correlation coefficient analysis
was employed to determine the relation between Rac1
activity and Pak1 expression. Rac1 activity and Pak1
expression, as well as tumor grade, pT stage, lymph node
metastasis, and LVI, were assessed for their relation to
disease-free survival and overall survival by univariate
and multivariate analyses with the Cox proportional haz-
ards model. The Kaplan-Meier method was used to esti-
mate survival, and differences of survival were assessed
by the log-rank test. Probability values of less than 0.05
were considered significant. Data were analyzed with
commercially available software.
Results
Association of Rac1 activity and Pak1 expression with 
tumor characteristics
Rac1 and Pak1 proteins were detected in tumor tissues,
non-tumor tissues, metastatic lymph nodes, and normal
lymph nodes (Figures. 1, 2). The level of active (GTP-
bound) Rac1 was significantly increased in tumor tissues
(mean ± S.D. = 2.72 ± 1.72) and metastatic lymph nodes
(1.86 ± 0.34) compared with the level in non-cancerous
tissues, which was set at 1.0 [21-23], (P < 0.0001, Figure.
3A). An increase of Rac1 activity in primary tumors wasKamai et al. BMC Cancer 2010, 10:164
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associated with poorly differentiated cancer (grade 1; 2.38
± 1.38, grade 2; 2.33 ± 1.31, grade 3; 3.30 ± 2.08, P =
0.0471, Figure. 3B), local invasion (<pT1; 2.38 ± 1.35, pT2;
2.32 ± 1.31, pT3; 2.91 ± 1.69, pT4; 4.46 ± 3.14, P = 0.1417,
Figure. 3C), lymph node metastasis (pN0; 2.55 ± 1.62,
pN1-3; 3.52 ± 1.96, P < 0.05, Figure. 3D), and LVI (LVI(-);
2.04 ± 0.97, LVI(+); 3.40 ± 2.02, P < 0.0001, Figure. 3E).
The level of Pak1 protein was significantly higher in
tumor tissues (mean ± S.D. = 2.68 ± 1.26) and metastatic
lymph nodes (2.77 ± 1.60) than the level in non-cancer-
ous tissues, which was also set at 1.0 [21-23], (P < 0.0001,
Figure. 4A). Higher expression of Pak1 protein in the pri-
mary tumor was associated with poorly differentiated
cancer (grade 1; 1.67 ± 0.34, grade 2; 2.38 ± 0.96, grade 3;
3.29 ± 1.45, P < 0.0001, Figure. 4B), local invasion (<pT1;
1.89 ± 0.60, pT2; 2.52 ± 0.97, pT3; 3.09 ± 1.12, pT4; 4.56 ±
2.10, P < 0.0001, Figure. 4C), lymph node metastasis
(pN0; 2.43 ± 1.09, pN1-3; 3.84 ± 1.35, P < 0.0001, Figure.
4D), and LVI (LVI(-); 2.03 ± 0.68, LVI(+); 3.34 ± 1.36, P <
0.0001, Figure. 4E).
We investigated the correlation between Rac1 activity
and Pak1 expression in tumor tissues. When Rac1 was
used as an independent variable and Pak1 as a dependent
variable, a positive correlation between them was
observed (r2 = 0.288, P < 0.0001, Figure. 5A). However, no
such correlation was observed in specimens of metastatic
lymph nodes (r2 = 0.307, P = 0.2602, Figure. 5B).
Prognostic influence of Rac1 activity and Pak1 expression
The mean level of Rac1 activity was 2.72 (± 1.72). Patients
were divided into two groups at this value, i.e., a high
activity group (46 patients) and a low activity group (62
Figure 1 Expression of GTP-binding (active form) Rac1 (22 kDa), Pak1 (65 kDa) and beta actin (42 kDa) proteins using Western blotting. M; 
marker, P; positive control using Hela cells, N; negative control, T1,2; tumor tissue, N1,2; non-tumor tissue. LN1; non-tumor lymph node, mLN1; meta-
static lymph node, Each number corresponds to a case number.Kamai et al. BMC Cancer 2010, 10:164
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patients), according to the method described previously
[21-23]. Similarly, the mean level of Pak1 protein expres-
sion in the tumor tissues was 2.68 (± 1.26), so a high
expression group (49 patients) and a low expression
group (59 patients) were separated by using this as the
cut-off value.
Kaplan-Meier plots of survival for patients with low
versus high levels of Rac1 activity showed that increased
Rac1 activity was associated with a shorter overall sur-
vival time (P < 0.0001, Figure. 6A). High expression of
Pak1 protein was also correlated with shorter overall sur-
vival (P < 0.0001, Figure. 6B). Univariate analysis of over-
all survival with the Cox proportional hazards model
revealed that tumor grade, pT stage, lymph node metas-
tasis, LVI, active Rac1, and Pak1 were all significant vari-
ables (Table 1). However, multivariate analysis revealed
that only LVI and Pak1 had an independent influence on
overall survival.
With regard to disease-free survival of the patients who
w e r e  N 0  M 0  a t  t h e  t i m e  o f  n e p h r o u r e t e r e c t o m y  ( 9 2
patients), the mean level of Rac1 activity and Pak1
expression in tumor tissue was 2.55 ± 1.62 and 2.43 ±
1.09, respectively. Comparison of Kaplan-Meier plots for
the N0 M0 patients with low Rac1 activity (59 patients)
versus high Rac1 activity (33 patients) showed that high
Rac1 activity was associated with a shorter disease-free
survival time (P  = 0.001, Figure. 6C). Similarly, higher
expression of Pak1 was a significant unfavorable factor
for disease-free survival (P  < 0.0001, Figure. 6D).
Although tumor grade, pT stage, LVI, active Rac1, and
Pak1 were all significant factors by Cox univariate analy-
s i s ,  o n l y  L V I  a n d  P a k 1  w e r e  i n d e p e n d e n t  v a r i a b l e s
according to multivariate analysis (Table 1).
With regard to the site of first postoperative recurrence
among the 92 N0 M0 patients, the Rac1 activity and Pak1
protein levels in the primary tumor tissues of patients
with retroperitoneal lymph node metastasis (PRLN) (n =
14; 3.99 ± 1.82, 3.61 ± 0.94, respectively) and other organ
metastases (3 of lung, one of liver, and one of bone; 6.35 ±
2.35 and 4.49 ± 1.90, respectively) were significantly
higher than the levels in patients with bladder recurrence
(n = 18; 1.95 ± 0.89, P < 0.0001, 2.32 ± 1.02, P < 0.01,
respectively, Figures. 3F, 4F). Furthermore, we divided
this group into two subgroups to study the relationship
between LVI and Rac1 activity or Pak1 expression (Fig-
ure. 7). When the PRLN and distant organs were the first
site of recurrence, the primary tumors had LVI, while pri-
mary tumors without LVI showed no PRLN recurrence or
distant metastasis. Among the LVI(+) group, both Rac1
activity and Pak1 expression in the primary tumors were
higher in patients with RPLN and distant metastases than
in those with bladder recurrence. The patients with blad-
der recurrence had higher tumor levels of Pak1 expres-
sion than those with no evidence of disease (NED), but
Rac1 activity did not vary. On the other hand, in the LVI(-
) group, both Rac1 activity and Pak1 expression were not
different between the primary tumors of patients with
bladder recurrence and those with NED. Interestingly,
a l t h o u g h  R a c 1  a c t i v i t y  s h o w e d  n o  d i f f e r e n c e  b e t w e e n
LVI(+) and LVI(-) tumors in patients with bladder recur-
rence, Pak1 expression was higher in the former tumors.
M-VAC therapy was performed for 16 patients with
lymph node metastasis at the time of nephroureterec-
tomy, 14 patients with postoperative lymph node involve-
ment, and 5 patients with postoperative metastasis to
other organs. All of these 35 patients eventually died of
progressive cancer. Their primary tumors were all LVI(+)
on pathological examination, as well as showing
increased Rac1 activity and high Pak1 expression (data
not shown).
Discussion
Rac1 and Pak1 have recently been shown to be key regu-
lators of cancer cell signaling networks, and there are sev-
eral lines of evidence linking Rac1 and Pak1 to the
acquisition of migratory, invasive, and metastatic pheno-
types [7,9]. In order to take into account possible inter-
Figure 2 Immunohistochemistry for Rac1 (upper panel) and Pak1 
(lower panel) proteins in Grade 3 carcinoma. Cytosolic compart-
ments shows intensely brown staining in most of the cancer cells, dis-
playing high Rac1 and Pak1 protein levels, but the nuclei of the cancer 
cells shows very weak staining.Kamai et al. BMC Cancer 2010, 10:164
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individual variations of Rac1 activity and Pak1 protein
expression in UC-UUT, we performed a comparison
among paired samples of tumor tissue, metastatic lymph
node tissue, and non-tumor tissue from the same patient.
The present study showed that Rac1 activity and Pak1
expression were significantly increased in primary
Figure 3 The relative expression levels of GTP-binding active Rac1 protein in tumor to those in corresponding non-tumor portion, which 
was set to 1.0. A; Expression in tumor, non-tumor, and lymph node tissues with metastasis (mLNs) and without (LN). B; Expression in Grade. C; Expres-
sion in pT stage. D; Expression in lymph node metastasis. pN(-) is pN0. pN(+) is pN1-3. E; Expression in lymphovascular invasion (LVI). F; Expression in 
first recurrence site. There were no difference between bladder and none of recurrence. The data show the 95% confidential interval.Kamai et al. BMC Cancer 2010, 10:164
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Page 7 of 13
Figure 4 The relative expression levels of Pak1 protein in tumor to those in corresponding non-tumor portion, which was set to 1.0. A; Ex-
pression in tumor, non-tumor, and lymph node tissues with metastasis (mLNs) and without (LN). B; Expression in Grade. C; Expression in pT stage. D; 
Expression in lymph node metastasis. pN(-) is pN0. pN(+) is pN1-3. E; Expression in lymphovascular invasion (LVI). F; Expression in first recurrence site. 
There were no difference between bladder and none of recurrence. The data show the 95% confidential interval.Kamai et al. BMC Cancer 2010, 10:164
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tumors and metastatic lymph nodes compared with non-
tumor tissues. Also, an increase of Rac1 activity and Pak1
expression in the primary tumor was correlated with
poorly differentiated cancer, local invasion, lymph node
metastasis, LVI, and an unfavorable prognosis. To our
knowledge, this is the first report about Rac1 and Pak1 in
UC-UUT. Our data suggested that Rac1 and its down-
stream effector Pak1 may be involved in the progression
of this cancer.
As well as our findings in patients with UC-UUT, over-
expression of Rac1 and Pak1 has been reported in several
other human cancers [7,9]. Moreover, an increase of Rac1
and Pak1 activity or overexpression have been observed
in breast cancer tissues and metastatic lymph nodes
[24,25]. In the present study, increased Rac1 activity and
higher Pak1 expression in the primary tumors was related
to muscle invasion and lymph node metastasis. There-
fore, it is likely that Rac1 and Pak1 have a role in deter-
mining the local invasive and metastatic potential of
various human cancers.
Regarding the site of initial postoperative recurrence in
patients who were pTanypN0 M0 at the time of neph-
roureterectomy, patients with postoperative lymph node
recurrence had a worse prognosis than those with blad-
der recurrence, probably because many bladder cancers
were detected at the superficial stage by active surveil-
lance. In the present study, LVI, Pak1 activity, Rac1, pT
stage, and tumor grade were related to postoperative
recurrence according to univariate analysis, with both
LVI and Pak1 still being significant determinants accord-
ing to multivariate analysis. As shown in Figure 7, Rac1
activity and Pak1 expression were higher in the primary
tumors of patients with postoperative lymph node metas-
tasis than in those of patients with bladder recurrence
from the LVI(+) group, but not the LVI(-) group. Pak1
expression was higher in the tumors of patients with
bladder recurrence than in recurrence-free patients from
the LVI(+) group, but Rac1 did not differ between them.
Moreover, all patients with lymph node involvement at
nephroureterectomy had LVI(+) tumors on pathological
examination. Therefore, LVI might be an important step
along the road to lymph node metastasis. Primary tumors
with LVI(+) and lymph node metastasis showed an
increase of Rac1 activity and Pak1 expression, while met-
astatic lymph node tissues showed higher Rac1 activity
and Pak1 expression than normal lymph nodes, indicat-
ing that Rac1 and Pak1 are involved in tumor metastasis.
However, it is unclear whether Rac1 and Pak1 play a simi-
lar role in lymph node metastasis and bladder recurrence.
It is well known that urothelial cancer often behaves like a
field change disease, with multiple occurrences and
recurrences due to implantation and migration, making it
difficult to determine whether a recurrent tumor has
been caused by tumor cell implantation, migration, or
multifocal carcinogenesis [26]. A recent molecular study
revealed that UC-UUT might be less genetically stable
than bladder tumors [27]. Therefore, an increase of Rac1
activity and upregulation of Pak1 expression might play a
role in lymph node metastasis of UC-UTT after neph-
roureterectomy, rather than contributing to bladder
recurrence. The differences of molecular mechanisms
between LVI and lymph node metastasis or bladder
recurrence need to be investigated further. On the other
hand, a previous study of bladder cancer showed that
Figure 5 Spearman rank correlation coefficient relationship between expression levels of Rac1 activity and Pak1. X axis is an independent 
variable. Y axis is a dependent variable. A; Tumor tissues. B; Metastatic lymph node tissues.Kamai et al. BMC Cancer 2010, 10:164
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high Pak1 expression was associated with a higher risk of
recurrence, even in patients with low grade/stage tumors
[28]. Taken together, therefore, it is likely that Pak1 and
Rac1 both play an important role in the invasion, metas-
tasis, and recurrence of urothelial cancer.
Although Pak1 is well known as a downstream effector
of Rac1, there have been few simultaneous analyses of
Rac1 and Pak1 expression in human tumor tissues. Our
study showed a positive correlation between Rac1 activity
and Pak1 expression in tumor tissue, while no such rela-
tion was observed in metasta tic lym ph node tissue. In
contrast to investigation of Rac1 activity, we only mea-
sured Pak1 protein expression, but we could still deter-
mine the approximate relation between the two
molecules. As shown in Figure 5, there was a positive cor-
relation in tumor tissues, but the absolute correlation was
fairly weak and no correlation was found in metastatic
lymph nodes. Pak1 is the best-characterized downstream
effector of Rac1, but it is also an important convergence
point for many signaling pathways (including small
GTPases and several tyrosine kinases) that are often acti-
vated in cancer cells [9-11]. Therefore, several oncogenic
pathways may act through Pak1 to promote cancer pro-
gression, so that Pak1 protein expression had a greater
impact on overall and recurrence-free survival than Rac1
activity in the present study. We did not assess Pak1 activ-
ity in this study, so its activity in tumor tissues needs to be
elucidated in the future.
Cell migration is central to metastasis by malignant
tumors [3]. Members of the Rho small GTPases family
regulate formation of stress fibers, focal adhesions, and
cell migration through reorganization of the actin
cytoskeleton [6]. Several lines of evidence have directly
linked Rac1 and Pak1 to acquisition of a migratory, inva-
sive, and metastatic phenotype and to a variety of pro-
cesses that occur in tumors, including cell
transformation, survival, invasion, metastasis, and angio-
genesis [7,9]. Our findings suggested that Rac1 and Pak1
were associated with L VI and RPLN, as well as distant
metastasis of UC-UUT.
Figure 6 Survival curve in the patients based on the mean values of Rac1 activity and Pak1 in primary tumor tissues, the cases were divided 
into two groups at this levels - high and low expression. A; Overall survival curve based on Rac1 activity in all patients. B; Overall survival curve 
based on Pak1 in all patients. C; Disease-free survival curve based on Rac1 activity in N0 M0 patients at nephroureterectomy. D; Disease-free survival 
curve based on Pak1 in N0 M0 patients at nephroureterectomy. P value was analyzed by log-rank test.K
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Table 1: Cox regression analysis for various potential prognostic factors in survival
Overall survival in all patients Disease-free survival in N0 M0 patients at 
nephroureterectomy
Variable Unfavorable/
favorable 
characteristics
No. of 
Patients
Analysis Relative
risk
95% 
confidential
interval
P value No. of 
Patients
Analysis Relative
risk
95% 
confidential
interval
P value
Univariate (U) 2.626 1.486 - 4.641 0.0009 Univariate (U) 1.947 1.117-3.392 0.0187
Grade 3/2/1 44/54/10 32/51/9
Multivariate (M) 1.008 0.488 - 2.083 0.6126 Multivariate 
(M)
1.047 0.427 - 1.678 0.6332
U 3.138 2.065 - 4.768 < 0.0001 U 1.905 1.308 - 2.774 0.0008
pT 4/3/2/1 > 8/41/31/28 3/37/26/26
M 1.499 0.837 - 2.526 0.1454 M 1.291 0.479 - 1/302 0.3551
U 3.049 2.005 - 4.636 < 0.0001
pN (+)/(-) 16/92
M 1.48 0.894 - 2.448 0.1271
U 11.024 5.550 - 21.896 < 0.0001 U 10.298 4.737 - 22.388 < 0.0001
LVI (+)/(-) 56/52 40/52
M 6.923 2432 - 19.707 < 0.0001 M 9.954 4.093 - 24.204 < 0.0001
U 4.363 2.188 - 8.702 < 0.0001 U 2.917 1.494 - 5.694 0.0017
Rac1 high/low 46/62 33/59
M 1.87 0.863 - 4.094 0.1223 M 1.323 0.627 - 2.791 0.4621
U 12.633 4.869 - 32.776 < 0.0001 U 4.814 2.384 - 9.721 < 0.0001
Pak1 high/low 49/59 35/57
M 3.635 1.230 - 10.741 0.0196 M 3.526 1.564 - 7.946 0.0024Kamai et al. BMC Cancer 2010, 10:164
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The renal pelvis and ureter have thin walls and a rich
lymphatic drainage [1], so many patients present with
local invasion and/or lymph node metastasis, while delay
in making the initial diagnosis is correlated with a higher
stage at presentation. Preoperative staging by CT/MRI
was very useful for detecting patients with local invasion
and/or lymph node metastasis in the present study, but
the prognosis of such patients was poor (Table 1).
Although systemic M-VAC therapy reduced the tumor
burden of our patients with urothelial cancer, the progno-
sis was worse than we expected [17]. In the present study,
M-VAC therapy was performed as adjuvant chemother-
apy for the 35 patients who showed lymph node or dis-
t a n t  m e t a s t a s i s  a t  s u r g e r y  o r  d u r i n g  p o s t o p e r a t i v e
surveillance, but all of these patients died of their cancer.
These 35 tumors were all LVI(+) and showed increased
Rac1 activity and high Pak1 expression. Furthermore, an
increase of Rac1 activity and a higher Pak1 e xpression
were associated with a shorter overall survival time in all
patients and shorter postoperative disease-free survival
in pTanypN0 M0 patients, indicating that Rac1 activity
and Pak1 expression may be useful prognostic indicators
for UC-UTT. These findings suggests that patients with
L VI(+) tumors that have higher Rac1 activity and Pak1
expression are at more risk of developing postoperative
RPLN or distant metastases in comparison to patients
without these markers. Therefore, we need to assess the
potential of chemotherapy for patients who have
pTanypN0 M0 tumors that are LVI(+) with increased Rac1
activity and Pak1 expression to prevent RPLN recurrence
Figure 7 Rac1 activity (A) and protein levels of Pak1 (B) regarding with postoperative first recurrence site among N0 M0 cases (92 patients). 
The data show the 95% confidential interval.Kamai et al. BMC Cancer 2010, 10:164
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or distant metastasis by performing a randomized study
in the future. In premenopausal breast cancer patients,
Pak1 overexpression has been closely linked with tamox-
ifen resistance of tumors [29]. On the other hand, several
low molecular weight inhibitors have been shown to
interfere with Pak1 kinase activity or function [9]. There-
fore, the Rac1-Pak1 pathway might be a potential thera-
peutic target for the prevention of tumor invasion and
metastasis by inhibition of this signaling pathway.
Accordingly, we should examine the effects of various
inhibitors using cell lines or tumor tissue samples. Fur-
thermore, as the Rac family has three isoforms and the
Pak family has six isoforms, each isoform may play a dif-
ferent role. Therefore, it is necessary to investigate each
of these isoforms in human cancers, and the information
thus obtained may shed new light on treatment strategies
for UC-UTT and other tumors.
Conclusion
In the present study, increased Rac1 activity and
increased expression of Pak1 (a major downstream effec-
tor) were associated with poorly differentiated tumors,
local invasion, LVI, lymph node metastasis, and an unfa-
vorable prognosis. Our findings suggest that the Rac1-
Pak1 pathway may be related to the progression of UC-
UUT and that these molecules may be indicators for this
disease.
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